ETON logo

ETON PHARMACEUTICALS INC

ETONNASDAQ
πŸ† #2135 by market capEarnings Nov 5US Equity
β€”β€”
Quote unavailable
πŸ””
Track ETON
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.47B
Small Cap
πŸ“ˆRevenue Growth (YoY)
81.5%
High Growth
πŸ“ŠGross Margin
57.9%
Healthy
πŸ’΅FCF Margin
18.0%
Healthy
βš–οΈP/S Ratio
13.8x
Elevated
Otter Score
64
Fair
No chart data available for ETON.

Trading Snapshot

Day Range
β€”
52-Week Range
$14.27 – $66.37
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
28.6M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$80M
Last Q Revenue
$38M
P/E Ratio
115.1
P/S Ratio
13.8x
EPS (TTM)
$0.39
Dividend Yield
β€”
Dilution (1yr)
+3.0%
ETON logo

ETON PHARMACEUTICALS INC

ETON
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$80Mβ–² +104.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
53.5%β–Ό βˆ’10.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$72Kβ–Ό βˆ’102.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10Mβ–² +980.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
26.9Mβ–² +3.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$17Mβ–² +$32M YoY
StockOtter Β· stockotter.space

About ETON PHARMACEUTICALS INC

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100
Analyst data unavailable.

Latest News & Updates

News unavailable.